Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 2/20 | 0.43 |
| ▸ | ROCK1 | Q13464 | 2/20 | 0.43 |
| ▸ | TNIK | Q9UKE5 | 4/20 | 0.39 |
| ▸ | TACR1 | P25103 | 11/20 | 0.38 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | FPR1 | P21462 | 1/20 | 0.37 |
| ▸ | GPR183 | P32249 | 1/20 | 0.37 |
| ▸ | APLNR | P35414 | 1/20 | 0.37 |
| ▸ | GLP1R | P43220 | 1/20 | 0.37 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.37 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.37 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.36 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4513882 | 0.88 | ROCK2 (0.44) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL7778436 | 0.87 | ROCK2 (0.42) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL7783684 | 0.87 | ROCK2 (0.41) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL7697384 | 0.85 | ROCK2 (0.40) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6794050 | 0.85 | ROCK2 (0.44) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6794717 | 0.85 | ROCK2 (0.42) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6793859 | 0.84 | ROCK2 (0.43) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6794230 | 0.84 | ROCK2 (0.43) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6795924 | 0.84 | ROCK2 (0.43) | ROCK2ROCK1TNIKTACR1ADRB2 | |
| SCHEMBL6790363 | 0.84 | ROCK2 (0.42) | ROCK2ROCK1TNIKTACR1ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | NATSUGARI HIDEAKI (JP) | 2002-09-19 | — | — | US | disclosed |
| EP-1184036-A2 | Heterocyclic compounds, their production and use as tachykinin receptor antagonists | Takeda Chemical Industries, Ltd. (JP) | 2002-03-06 | — | — | EP | disclosed |
| CN-1291099-A | Heterocyclic compounds, their production and use | TAKEDA CHEMICAL INDUSTRIES LTD (JP) | 2001-04-11 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020132817-A1 | Heterocyclic compounds, their production and use | CRH, CRHR1, CRHR2 | ROCK2 1761/4885ROCK1 1349/4885TNIK 2301/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.